NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
nanoRETE, Inc. provides real-time detection of pathogens using customized nanoparticle biosensors. The company has developed a platform that has the ability to test for numerous pathogens (anthrax, E. Coli, salmonella, tuberculosis, etc.) using a simple-to-use handheld device which generates screening results in about one hour.
NanoStar Health aims to become a global leader in the emerging technology arena of nanomedical devices specifically designed for premature infants. The Company began operations in March 2009 and was incorporated in May 2009 to capitalize on the founder's expertise in nanotechnology, neonatal and pediatric medicine, and medical device commercialization.
A nanotechnology-based platform for single molecule identification and digital quantification. The NanoString™ system uniquely barcodes individual target molecules, scans them, and delivers a literal inventory of target molecules in the biological sample.
The company's nanofluidization process utilizes a proprietary nanotechnology process which allows molecules to be embedded into nanosuspensions (or nanodroplets) and microdroplets of between about 10 nm to about 10 µm in size, which are used to create highly solulable, stable and uniform emulsions/dispersions.
NanoTemper Technologies GmbH, a Spin-Off of the Ludwig-Maximilians-University Munich, was founded in May 2008 in order to provide analytical services to pharmaceutical industry, biotechnology and research institues.
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate the delivery of foreign DNA into living cells.
nanoTools provides monoclonal and polyclonal antibody development services and products. Besides providing individually tailored custom solutions, the company develops, manufactures and markets phosphorylation and modification - state specific monoclonal antibodies and other innovative reagents for Signal Transduction and Alzheimer research, high throughput screening (HTS) and proteomics.
An early stage therapeutic drug company, NanoVector Inc. is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University. The NanoVector nanoparticle is a plant virus. Central to our technology, this virus, which has evolved over millions of years, has several inherent characteristics essential for a successful nanoparticle delivery system and superior to any designed and engineered by humans.
Nanoxis is a biotechnology company with extensive knowledge and experience in membrane protein research. Nanoxis has nanoscale technology solutions based on soft polymer and fluid-state liquid crystalline materials. The company is working on research and development of new nanofabrication technologies in soft polymer and fluid-state liquid crystalline material. These technologies are applicable for production of biochips used in proteomics and genetics and as advanced components for nanofluidics, nanoelectronics and robotics.
Nicast Ltd. develops superior medical devices from electrospun nanofabric for a wide range of clinical applications. Electrospun nanofabric is a biomaterial made of ultra-thin polymer fibers, with properties that mimic those of human tissues and organs.
Nicoya Lifesciences is a company developing innovative medical diagnostic products using nanotechnology. Their goal is to provide consumers with new diagnostic tools that are affordable, connected, and intuitive, allowing them better control over their own health and wellness. Nicoya is using a proprietary nanoparticle sensor for blood protein biomarker diagnostics.
NOD Pharmaceuticals uses patented platform technology, nanoparticle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.
Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms: Virus-Like Particles, NovasomeŽ paucilamellar vesicles and Micellar Nanoparticles.